Aurobindo Pharma receives US FDA nod for hypertension drug esmolol hydrochloride
Esmolol hydrochloride injection is generic version of Baxter Healthcare's Brevibloc injection
The US Food & Drug Administration (US FDA) has granted Aurobindo Pharma Limited final approval for manufacturing and marketing of esmolol hydrochloride injection in strength of 100 mg/10mL.
Esmolol hydrochloride injection is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Brevibloc injection of Baxter Healthcare Corporation. Esmolol hydrochloride injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period.
Esmolol hydrochloride injection is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Brevibloc injection of Baxter Healthcare Corporation. Esmolol hydrochloride injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period.